

FUROSCIX **(furosemide)** injection for subcutaneous use

RATIONALE FOR INCLUSION IN PA PROGRAM

Background

Furoscix (furosemide) primarily inhibits the reabsorption of sodium and chloride in the proximal and distal tubules and in the loop of Henle. The high degree of diuresis is largely due to the unique site of action. The action on the distal tubule is independent of any inhibitory effect on carbonic anhydrase and aldosterone (1).

Regulatory Status

FDA-approved indication: Furoscix is a loop diuretic indicated for the treatment of edema in adult patients with chronic heart failure or chronic kidney disease, including nephrotic syndrome (1).

Furoscix is not for chronic use and should be replaced with oral diuretics as soon as practical (1).

Furoscix contains warnings regarding the following: fluid, electrolyte, and metabolic abnormalities; worsening renal function; ototoxicity; and acute urinary retention (1).

The safety and effectiveness of Furoscix in pediatric patients less than 18 years of age have not been established (1).

Summary

Furoscix (furosemide) is a loop diuretic indicated for the treatment of edema in adults with chronic heart failure or chronic kidney disease. Furoscix is not for chronic use and should be replaced with oral diuretics as soon as practical. The safety and effectiveness of Furoscix in pediatric patients less than 18 years of age have not been established (1).

Prior approval is required to ensure the safe, clinically appropriate, and cost-effective use of Furoscix while maintaining optimal therapeutic outcomes.

References

1. Furoscix [package insert]. Burlington, MA: scPharmaceuticals, Inc.; March 2025.